指南与共识甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

分化型甲状腺癌的放射性碘治疗:剂量推荐与第二原发恶性肿瘤风险更新

Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
指南 / 共识 · Semin Nucl Med · 2024-05-21

本文综述了分化型甲状腺癌(DTC)中碘-131放射性碘(RAI)治疗的更新剂量推荐及第二原发恶性肿瘤(SPM)风险。截至2024年4月,多数医学学会推荐残留消融剂量为1.11 GBq(30 mCi),辅助治疗为1.11–3.7 GBq(30–100 mCi),已知或疑似转移者至少3.7 GBq(100 mCi)。RAI相关SPM风险研究结论不一,部分报告累积剂量超过5.6–7.4 GBq(150–200 mCi)时风险增加,但无法明确剂量阈值。

要点

  • 多数医学学会推荐残留消融使用1.11 GBq(30 mCi)碘-131。
  • 辅助治疗推荐1.11–3.7 GBq(30–100 mCi),可考虑高达5.6 GBq(150 mCi)。
  • 已知或疑似转移者至少3.7 GBq(100 mCi),视肿瘤负荷可高达7.4 GBq(200 mCi)。

核心结论

  • RAI剂量通常基于肿瘤复发风险评估等因素经验性选择,各医学学会推荐略有差异。
  • RAI相关SPM风险存在持续争议,部分研究显示风险未增加,部分报告高累积剂量与风险增加相关。
  • 当前文献无法提供明确SPM剂量阈值,需进一步研究以更好理解RAI剂量与SPM风险的关系。

研究设计与样本

  • 本文为综述,汇总截至2024年4月各医学学会的RAI剂量推荐及近2年发表的多中心研究和Meta分析关于SPM风险的结果。

主要发现

  • 多数医学学会推荐残留消融剂量为1.11 GBq(30 mCi)碘-131。
  • 辅助治疗推荐RAI剂量范围为1.11–3.7 GBq(30–100 mCi),也可考虑高达5.6 GBq(150 mCi)。
  • 已知或疑似转移性疾病患者应给予至少3.7 GBq(100 mCi),根据疑似肿瘤负荷和范围可高达7.4 GBq(200 mCi)。
  • 剂量学方法可根据每位患者药代动力学调整RAI剂量,多数情况下导致≥7.4 GBq(200 mCi)的碘-131。
  • 部分报告显示累积RAI剂量超过5.6–7.4 GBq(150–200 mCi)与SPM风险增加相关,但无法明确剂量阈值。

关键数值与推荐

  • 美国甲状腺协会(ATA)、欧洲甲状腺协会(ETA)、核医学与分子影像学会/欧洲核医学协会(SNMMI/EANM)及国家综合癌症网络(NCCN)推荐残留消融剂量为1.11 GBq(30 mCi)碘-131。
  • 辅助治疗推荐RAI剂量范围为1.11–3.7 GBq(30–100 mCi),也可考虑高达5.6 GBq(150 mCi)。
  • 已知或疑似转移性疾病患者应给予至少3.7 GBq(100 mCi)碘-131,根据疑似肿瘤负荷和范围可高达7.4 GBq(200 mCi)。
  • 剂量学方法多数情况下导致≥7.4 GBq(200 mCi)的碘-131。

临床怎么用

  • 对于持续转移性甲状腺乳头状癌(PTC)考虑重复RAI治疗且累积剂量超过37.0 GBq(1,000 mCi)时,应谨慎,因存在SPM和其他长期毒性的潜在风险。
  • 原文未据此给出其他推荐。

局限性

  • RAI相关SPM发生率因研究设计和检测方法而异。
  • 部分研究显示SPM发生率未增加,且无特定继发癌症或癌症组与RAI暴露相关。
  • 部分报告显示累积RAI剂量超过5.6–7.4 GBq(150–200 mCi)与SPM风险增加相关,但基于当前文献无法提供明确剂量阈值。
  • 需进一步研究以更好理解RAI剂量与SPM风险的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioactive iodine (RAI) therapy with iodine-131 is performed in select cases of differentiated thyroid cancer (DTC), typically for remnant ablation, adjuvant therapy, or treatment of known persistent disease. Herein, we review updated RAI dose recommendations and associated risks of secondary primary malignancy (SPM). RAI dose is usually chosen empirically based on the risk assessment of tumor recurrence and other factors. Dose recommendations differ slightly among relevant medical societies. As of April 2024, most medical societies, including the American Thyroid Association (ATA), European Thyroid Association (ETA), Society of Nuclear Medicine and Molecular Imaging/European Association of Nuclear Medicine (SNMMI/ EANM), and National Comprehensive Cancer Network (NCCN), recommend a dose of 1.11 GBq (30 mCi) I-131 for remnant ablation. For adjuvant therapy, the recommended RAI dose ranges from 1.11 to 3.7 GBq (30-100) mCi I-131, although doses up to 5.6 GBq (150 mCi) may also be considered. In patients with known or suspected metastatic disease, at least 3.7 GBq (100 mCi) I-131 should be administered, and RAI doses as high as 7.4 GBq (200 mCi) may be justified depending on the suspected tumor burden and extent. Dosimetry has the advantage of tailoring the RAI dose to each patient's pharmacokinetics, resulting in ≥ 7.4 GBq (200 mCi) of I-131 in most cases. There is an ongoing debate about the risk of developing SPM due to RAI therapy, with several multicenter studies and meta-analyses concerning SPM being published in the last 2 years. The incidence of RAI-associated SPM varies according to the study design and detection method. Several studies showed no increased incidence, and there was no specific secondary cancer or cancer group linked to RAI exposures. Some reports indicated that cumulative RAI doses exceeding 5.6-7.4 GBq (150-200 mCi) were found to represent an increased risk for developing SPM. However, a clearly defined dose threshold cannot be provided based on the current literature. Nonetheless, caution should be exercised when considering repeated RAI therapies for persistent metastatic PTC, with a cumulative dose exceeding 37.0 GBq (1,000 mCi), due to the potential risk of developing SPM and other long-term toxicity. Further research is warranted to understand better the relationship between RAI dose and the risk of SPM.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nguyen NC, Anigati EM, Desai NB, et al. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies. Semin Nucl Med. 2024. PMID: 38772827. doi:10.1053/j.semnuclmed.2024.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。